


Amendments to the Claims:

This listing of claims will replace all prior versions and listing of claims in this application.

Please amend claims 1 to 4, 17 to 28 and 31 to 33 as indicated.

Please cancel claims 29, 30 and 34 to 42 without prejudice or disclaimer.

1. (currently amended): A compound of Formula I:



~~or a solvate, hydrate, tautomer~~ or pharmaceutically acceptable salt thereof, wherein

R is

-OH or -NHOR_a, wherein R_a is hydrogen, alkyl, cycloalkyl, aryl or aralkyl;

A₁ is

a 5- to 6-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C₁₋₆ alkyl, amino, alkylamino, halogen, hydroxy, alkoxy, -OCO-alkyl, -OCO-alkylamino, -OCO-alkylamido, aryloxy, arylalkoxy, -CF₃, -OCF₃, -COR_a, -COOR_a, -CONR_aR_b, -NHCOR_aR_b, -NH₂SO₂R_a, -SO₂R_a, -SO₃R_a or -SO₂NR_aR_b, wherein R_a and R_b are independently hydrogen, alkyl, cycloalkyl, aryl or aralkyl;

R₁ is

hydrogen, alkyl, hydroxy or alkoxy;

R₂ is

hydrogen, alkyl, carboxyalkyl, cycloalkyl, heterocyclalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, hydroxyalkyl, aminoalkyl, hydroxy, alkoxy or polyalkoxyalkyl;

R₃ is
a direct link or
C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ thioalkyl, C₁₋₆ hydroxyalkyl or C₁₋₆ carboxyalkyl; and


A₂ is
phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of C₁₋₄ alkyl, amino, aminoalkyl, halogen, hydroxy, -CF₃, alkoxy, aryloxy, arylalkoxy, -OCF₃, -COR_c, -COOR_c, -CONR_cR_d, -N(R₁)COR_c, -SO₂R_c, -SO₃R_c or -SO₂NR_cR_d;

a 5- to 7-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C₁₋₆ alkyl, amino, halogen, hydroxy, alkoxy, aryloxy, arylalkoxy, -CF₃, -OCF₃, -COR_c, -COOR_c, -CONR_cR_d, -NHCOR_cR_d, NH₂SO₂R_c, -SO₂R_c, -SO₃R_c or -SO₂NR_cR_d; or

-COR_c, -COOR_c or -CONR_cR_d, wherein

R_c and R_d are independently hydrogen, alkyl, cycloalkyl, aryl, aralkyl, heteroaralkyl or heteroaryl.

2. (currently amended): A compound of Formula II:



~~or a solvate, hydrate, tautomer~~ or pharmaceutically acceptable salt thereof, wherein

R is
-COR_a, -CONR_aR_b, -SO₂R_a or -PO₃R_aR_b, wherein R_a and R_b are independently hydrogen, alkyl, cycloalkyl, polyalkoxyalkyl, aryl or aralkyl;

A₁ is
a 5- to 6-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring

having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C₁₋₆ alkyl, amino, alkylamino, halogen, hydroxy, alkoxy, -OCO-alkyl, -OCO-alkylamino, -OCO-alkylamido, aryloxy, arylalkoxy, -CF₃, -OCF₃, -COR_c, -COOR_c, -CONR_cR_d, -NHCOR_cR_d, -NHSO₂R_c, -SO₂R_c, -SO₃R_c or -SO₂NR_cR_d, wherein R_c and R_d are independently hydrogen, alkyl, cycloalkyl, aryl or aralkyl;

R₁ is
hydrogen, alkyl, hydroxy or alkoxy;

R₂ is
hydrogen, alkyl, carboxyalkyl, cycloalkyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, hydroxyalkyl, aminoalkyl, hydroxy, alkoxy or polyalkoxyalkyl;

R₃ is
a direct link or
C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ thioalkyl, C₁₋₆ hydroxyalkyl or C₁₋₆ carboxyalkyl; and


A₂ is
phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of C₁₋₄ alkyl, amino, aminoalkyl, halogen, hydroxy, -CF₃, alkoxy, aryloxy, arylalkoxy, -OCF₃, -COR_e, -COOR_e, -CONR_eR_f, -N(R₁)COR_e, -SO₂R_e, -SO₃R_e or -SO₂NR_eR_f;

a 5- to 7-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C₁₋₆ alkyl, amino, halogen, hydroxy, alkoxy, aryloxy, arylalkoxy, -CF₃, -OCF₃, -COR_e, -COOR_e, -CONR_eR_f, -NHCOR_eR_f, NHSO₂R_a, -SO₂R_a, -SO₃R_a or -SO₂NR_aR_b; or

-COR_e, -COOR_e or -CONR_eR_f, wherein

R_e and R_f are independently hydrogen, alkyl, cycloalkyl, aryl, aralkyl, heteroaralkyl or heteroaryl.

3. (currently amended): A compound of Formula III:



or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein

R is

-OH or -NHOR_a, wherein R_a is hydrogen, alkyl, cycloalkyl, aryl or aralkyl;


A₁ is

a 5- to 6-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C₁₋₆ alkyl, amino, alkylamino, halogen, hydroxy, alkoxy, -OCO-alkyl, -OCO-alkylamino, -OCO-alkylamido, aryloxy, arylalkoxy, -CF₃, -OCF₃, -COR_a, -COOR_a, -CONR_aR_b, -NHCOR_aR_b, -NHCO₂R_a, -SO₂R_a, -SO₃R_a or -SO₂NR_aR_b, wherein R_a and R_b are independently hydrogen, alkyl, cycloalkyl, aryl or aralkyl;

R₁ is

hydrogen, alkyl, hydroxy or alkoxy; and

R₂ is



wherein

R_c and R_d are independently hydrogen or alkyl;

X is N, O or S; and


A₂ is

phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of C₁₋₄ alkyl, amino, aminoalkyl, halogen, hydroxy, -CF₃, alkoxy, aryloxy, arylalkoxy, -OCF₃, -COR_e, -COOR_e, -CONR_eR_f, -N(R₁)COR_e, -SO₂R_e, -SO₃R_e or

-SO₂NR_eR_f; or
a 5- to 7-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C₁₋₆ alkyl, amino, halogen, hydroxy, alkoxy, aryloxy, arylalkoxy, -CF₃, -OCF₃, -COR_e, -COOR_e, -CONR_eR_f, -NHCOR_eR_f, NHSO₂R_e, -SO₂R_e, -SO₃R_e or -SO₂NR_eR_f, wherein

R_e and R_f are independently hydrogen, alkyl, cycloalkyl, aryl, aralkyl, heteroaralkyl or heteroaryl.

4. (currently amended): A compound of Formula IV:



~~or a solvate, hydrate, tautomer~~ or pharmaceutically acceptable salt thereof, wherein

R is

-COR_a, -CONR_aR_b, -SO₂R_a or -PO₃R_aR_b, wherein R_a and R_b are independently hydrogen, alkyl, cycloalkyl, polyalkoxyalkyl, aryl or aralkyl;


A₁ is

a 5- to 6-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C₁₋₆ alkyl, amino, alkylamino, halogen, hydroxy, alkoxy, -OCO-alkyl, -OCO-alkylamino, -OCO-alkylamido, aryloxy, arylalkoxy, -CF₃, -OCF₃, -COR_c, -COOR_c, -CONR_cR_d, -NHCOR_cR_d, -NHCO₂R_c, -SO₂R_c, -SO₃R_c or -SO₂NR_cR_d, wherein R_c and R_d are independently hydrogen, alkyl, cycloalkyl, aryl or aralkyl;

R₁ is

hydrogen, alkyl, hydroxy or alkoxy; and

R₂ is



wherein

R_e and R_f are independently hydrogen or alkyl;

X is N, O or S; and

A_2 is


phenyl, naphthyl or biphenyl, each of which may be optionally substituted with one or more of C_{1-4} alkyl, amino, aminoalkyl, halogen, hydroxy, $-CF_3$, alkoxy, aryloxy, arylalkoxy, $-OCF_3$, $-COR_g$, $-COOR_g$, $-CONR_gR_h$, $-N(R_1)COR_g$, $-SO_2R_g$, $-SO_3R_g$ or $-SO_2NR_gR_h$; or

a 5- to 7-membered mono- or a 8- to 10-membered bicyclic heteroaromatic ring having from one to four heteroatoms selected from N, O or S, and may be optionally substituted with C_{1-6} alkyl, amino, halogen, hydroxy, alkoxy, aryloxy, arylalkoxy, $-CF_3$, $-OCF_3$, $-COR_g$, $-COOR_g$, $-CONR_gR_h$, $-NHCOR_gR_h$, $NHSO_2R_g$, $-SO_2R_g$, $-SO_3R_g$ or $-SO_2NR_gR_h$, wherein

R_g and R_h are independently hydrogen, alkyl, cycloalkyl, aryl, aralkyl, heteroaralkyl or heteroaryl.

5. (original): A compound of claim 1, wherein


A_1 is



wherein R_a and R_b are independently -H, $-C_{1-6}$ alkyl, $-CO_2$ -alkyl or $-CO_2-CH_2CH_2NH_2$;

R₁ is -H;


R₂ is
 -H, -Me, -Et,



wherein R_c is alkyl;

R₃ is
 -CH₂-, -CH₂CH₂-, -CH(CH₃)-, -C(CH₃)₂-, -CH(CH₂OH)- or
 -CH(CH₂CH₂COOH)-; and

A₂ is



wherein X is O or S.

6. (previously presented): A compound of Formula I according to claim 1, selected from

4-(Benzothiazol-6-ylamino)-6-(ethyl-benzylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(methyl-benzylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(benzylamino)-[1,3,5]triazin-2-ol;
(R)-4-(Benzothiazol-6-ylamino)-6-(1-phenylethylamino)-[1,3,5]triazin-2-ol;
(S)-4-(Benzothiazol-6-ylamino)-6-(1-phenylethylamino)-[1,3,5]triazin-2-ol;
(R)-4-(Benzothiazol-6-ylamino)-6-(methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;
(S)-4-(Benzothiazol-6-ylamino)-6-(methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;
(R)-4-(Benzothiazol-6-ylamino)-6-(ethyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;
(S)-4-(Benzothiazol-6-ylamino)-6-(ethyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(2-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(methyl-2-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(ethyl-2-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(2-chloro-benzylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(2-fluoro-benzylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[(pyridin-3-ylmethyl)-amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(2,6-difluoro-benzylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[methyl-(2-pyridin-2-yl-ethyl)amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[pyridin-2-ylmethyl)-amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[benzyl-(1-benzyl-pyrrolidin-3-yl)-amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(3-fluoro-benzylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(2-chloro-6-methyl-benzylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(N'-methyl-N'-phenyl-hydrazino)-[1,3,5]triazin-2-ol;
4-(benzothiazol-6-ylamino)-6-[(pyridin-4-ylmethyl)-amino]-[1,3,5]triazin-2-ol;
4-Benzothiazol-6-ylamino)-6-(2-pyridin-3-yl-ethylamino)-[1,3,5]triazin-2-ol;
4-Benzothiazol-6-ylamino)-6-(1-phenyl-propylamino)-[1,3,5]triazin-2-ol;
4-Benzothiazol-6-ylamino)-6-(2-pyridin-2-yl-ethylamino)-[1,3,5]triazin-2-ol;

4-(Benzothiazol-6-ylamino)-6-(1-naphthalen-1-yl-ethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(3-hydroxymethyl-phenylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(quinolin-5-ylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(4-hydroxy-naphthalen-1-ylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(1H-indazol-6-ylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[(1H-indazol-6-yl)-methylamino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(1-methyl-1H-indazol-6-ylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(6-hydroxy-naphthalen-1-ylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(3-hydroxy-phenylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[2-(2-hydroxyethyl)-phenylamino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(5-thiophen-2-yl-2H-pyrazol-3-ylamino)-[1,3,5]triazin-2-ol; 4-
(Benzothiazol-6-ylamino)-6-(2-phenyl-2H-pyrazol-3-ylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(2,4-difluoro-benzylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-phenylamino-[1,3,5]triazin-2-ol;
4-(1H-Indazol-6-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(2-hydroxy-1-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(1H-Indazol-5-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-7-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[(furan-2-yl-methyl)amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[(thiophen-2-yl-methyl)amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[(furan-3-ylmethyl)-amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[(thiophen-3-yl-methyl)amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-(benzyl-pyrrolidin-3-ylamino)-[1,3,5]triazin-2-ol;
3-{[4-(Benzothiazol-6-ylamino)-6-hydroxy-[1,3,5]triazin-2-yl]-benzylamino}-propane-1,2-diol;
4-(Benzothiazol-6-ylamino)-6-[benzyl-(3-morpholin-4-ylpropyl)-amino]-[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-{benzyl-[3-(4-methyl-piperazin-1-yl)-propyl]-amino}-
[1,3,5]triazin-2-ol;
4-(Benzothiazol-6-ylamino)-6-[benzyl-(3-dimethylamino-propyl)-amino]-[1,3,5]triazin-2-ol;

4-(Benzothiazol-6-ylamino)-6-[benzyl-(2-piperazin-1-ylethyl)-amino]-[1,3,5]triazin-2-ol; 4-(Benzothiazol-6-ylamino)-6-[benzyl-(2-morpholin-4-ylethyl)-amino]-[1,3,5]triazin-2-ol; 4-(Benzothiazol-6-ylamino)-6-[benzyl-(2-dimethylamino-ethyl)-amino]-[1,3,5]triazin-2-ol; 4-(2-Amino-benzothiazol-6-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol; 4-(1-Methyl-1-phenylethylamino)-6-(quinolin-6-ylamino)-[1,3,5]triazin-2-ol; 4-(Quinolin-6-ylamino)-6-(N-ethylbenzylamino)-[1,3,5]triazin-2-ol; 4-(Quinolin-6-ylamino)-6-(N-methylbenzylamino)-[1,3,5]triazin-2-ol; 4-(Quinolin-6-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-ol; N-[4-(Benzothiazol-6-ylamino)-6-(1-methyl-1-phenylethylamino)-[1,3,5]triazin-2-yl]-hydroxylamine;
or a pharmaceutically acceptable salt thereof.

7. (previously presented): A compound of Formula III according to claim 3, selected from

4-(Benzothiazol-6-yl-amino)-6-(2-methyl-pyrrolidin-1-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(2-benzyl-pyrrolidin-1-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(2,6-dimethyl-piperidin-1-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(2,5-dimethyl-pyrrolidin-1-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(2-phenyl-pyrrolidin-1-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(3-phenyl-thiomorpholin-4-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(2-phenyl-thiomorpholin-4-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(thiomorpholin-4-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(3-methyl-piperidin-1-yl)-[1,3,5]triazine-2-ol;
4-(Benzothiazol-6-yl-amino)-6-(morpholin-4-yl)-[1,3,5]triazine-2-ol;
or a pharmaceutically acceptable salt thereof.

8. (original): A pharmaceutical composition, comprising a compound of any one of claims 1 to 4 and a pharmaceutically acceptable carrier.

9. (original): A pharmaceutical composition, comprising a compound of claim 5 and a pharmaceutically acceptable carrier.

10. (original): A pharmaceutical composition, comprising a compound of claim 6 or 7 and a pharmaceutically acceptable carrier.

11. (original): A method of preparing the compounds of Formulae I and III where R is -OH, comprising the steps of:

- a) displacing one of three displaceable groups at the 2-, 4- and 6-positions, respectively, of a 1,3,5-triazine ring with 4-methoxybenzyl alcohol to give a 2-(4-methoxybenzyloxy)-[1,3,5]triazine;
- b) displacing the second displaceable group with a primary or secondary alkyl or aromatic amine (i) to give a 4-amino-2-(4-methoxybenzyloxy)-[1,3,5]triazine; and
- c) displacing the third displaceable group with a primary or secondary alkyl or aromatic amine (ii) under microwave conditions with concomitant loss of the p-methoxybenzyl group to give a 4,6-diamino-(2-hydroxy)-[1,3,5]triazine.

12. (original): A method of preparing the compounds of Formulae II and IV, comprising the steps of:

- a) displacing one of three displaceable groups at the 2-, 4- and 6-positions, respectively, of a 1,3,5-triazine ring with 4-methoxybenzyl alcohol to give a 2-(4-methoxybenzyloxy)-[1,3,5]triazine;
- b) displacing the second displaceable group with a primary or secondary alkyl or aromatic amine (i) to give a 4-amino-2-(4-methoxybenzyloxy)-[1,3,5]triazine;
- c) displacing the third displaceable group with a primary or secondary alkyl or aromatic amine (ii) under microwave conditions with concomitant loss of the p-methoxybenzyl group to give a 4,6-diamino-(2-hydroxy)-[1,3,5]triazine; and
- d) adding an acylating, sulfonylating or phosphorylating agent to the 4,6-diamino-(2-hydroxy)-[1,3,5]triazine to give a 4,6-diamino-(2-O-acyl)-[1,3,5]triazine, a 4,6-diamino-(2-O-sulfonyl)-[1,3,5]triazine or a 4,6-diamino-(2-O-phosphoryl)-[1,3,5]triazine, respectively.

13. (original): A method of claim 11 or 12, wherein the displaceable groups are chlorines.

14. (original): A method of preparing the compounds of Formulae I and III where R is -OH, comprising the steps of:

aa) displacing one of three displaceable groups at the 2-, 4- and 6-positions, respectively, of a 1,3,5-triazine ring with a primary or secondary alkyl or aromatic amine (i) to give a 2-amino-[1,3,5]triazine;

bb) displacing the second displaceable group with a primary or secondary alkyl or aromatic amine (ii) to give a 2,4-diamino-[1,3,5]triazine; and

cc) displacing the third displaceable group with water under acidic conditions to give a 4,6-diamino-(2-hydroxy)-[1,3,5]triazine.

15. (original): A method of preparing the compounds of Formulae I and III where R is -NHOH, comprising the steps of:

aa) displacing one of three displaceable groups at the 2-, 4- and 6-positions, respectively, of a 1,3,5-triazine ring with a primary or secondary alkyl or aromatic amine (i) to give a 2-amino-[1,3,5]triazine;

bb) displacing the second displaceable group with a primary or secondary alkyl or aromatic amine (ii) to give a 2,4-diamino-[1,3,5]triazine; and

cc) displacing the third displaceable group with hydroxylamine under acidic conditions to give a 4,6-diamino-([1,3,5]triazin-2-yl)-hydroxylamine.

16. (original): A method of preparing the compounds of Formulae II and IV, comprising the steps of:

aa) displacing one of three displaceable groups at the 2-, 4- and 6-positions, respectively, of a 1,3,5-triazine ring with a primary or secondary alkyl or aromatic amine (i) to give a 2-amino-[1,3,5]triazine;

bb) displacing the second displaceable group with a primary or secondary alkyl or aromatic amine (ii) to give a 2,4-diamino-[1,3,5]triazine;

cc) displacing the third displaceable group with water under acidic conditions to give a 4,6-diamino-(2-hydroxy)-[1,3,5]triazine; and

dd) adding an acylating, sulfonylating or phosphorylating agent to the 4,6-diamino-(2-hydroxy)-[1,3,5]triazine to give a 4,6-diamino-(2-O-acyl)-[1,3,5]triazine, a 4,6-diamino-(2-O-sulfonyl)-[1,3,5]triazine or a 4,6-diamino-(2-O-phosphoryl)-[1,3,5]triazine, respectively.

17. (currently amended): A method for inhibiting protein tyrosine kinase activity, comprising contacting the kinase with an effective inhibitory amount of at least one compound of any one of claims 1 to 4, **wherein the tyrosine kinase is VEGFR-2 (KDR).**

18. (currently amended): A method for inhibiting protein tyrosine kinase activity, comprising contacting the kinase with an effective inhibitory amount of at least one compound of claim 5, **wherein the tyrosine kinase is VEGFR-2 (KDR).**

19. (currently amended): A method for inhibiting protein tyrosine kinase activity, comprising contacting the kinase with an effective inhibitory amount of at least one compound of claim 6 or 7, **wherein the tyrosine kinase is VEGFR-2 (KDR).**

20. (currently amended): A method for inhibiting protein tyrosine kinase activity *in vitro*, comprising contacting the kinase with at least one compound of any one of claims 1 to 4, **wherein the tyrosine kinase is VEGFR-2 (KDR).**

21. (currently amended): A method for inhibiting protein tyrosine kinase activity *in vitro*, comprising contacting the kinase with at least one compound of claim 5, **wherein the tyrosine kinase is VEGFR-2 (KDR).**

22. (currently amended): A method for inhibiting protein tyrosine kinase activity *in vitro*, comprising contacting the kinase with at least one compound of claim 6 or 7, **wherein the tyrosine kinase is VEGFR-2 (KDR).**

23. (currently amended): A method for inhibiting protein tyrosine kinase activity in cells, comprising contacting the kinase with at least one compound of any one of claims 1 to 4,

wherein the tyrosine kinase is VEGFR-2 (KDR).

24. (currently amended): A method for inhibiting protein tyrosine kinase activity in cells, comprising contacting the kinase with at least one compound of claim 5, **wherein the tyrosine kinase is VEGFR-2 (KDR).**

25. (currently amended): A method for inhibiting protein tyrosine kinase activity in cells, comprising contacting the kinase with at least one compound of claim 6 or 7, **wherein the tyrosine kinase is VEGFR-2 (KDR).**

26. (currently amended): A method for inhibiting protein tyrosine kinase activity in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of any one of claims 1 to 4, **wherein the tyrosine kinase is VEGFR-2 (KDR).**

27. (currently amended): A method for inhibiting protein tyrosine kinase activity in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of claim 5, **wherein the tyrosine kinase is VEGFR-2 (KDR).**

28. (currently amended): A method for inhibiting protein tyrosine kinase activity in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of claim 6 or 7, **wherein the tyrosine kinase is VEGFR-2 (KDR).**

29-30. (cancelled).

31. (currently amended): A method of treating **breast** ~~tyrosine kinase-mediated~~ cancer in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of any one of claims 1 to 4.

32. (currently amended): A method of treating **breast** ~~tyrosine kinase-mediated~~ cancer in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of claim 5.

33. (currently amended): A method of treating breast ~~tyrosine kinase mediated~~ cancer in a mammal, comprising administering to the mammal a therapeutically effective amount of at least one compound of claim 6 or 7.

34-42. (cancelled).

43. (original): A pharmaceutical dosage form comprising a pharmaceutically acceptable carrier and from about 0.5 mg to about 10 g of at least one compound of any one of claims 1 to 7.

44. (original): A dosage form according to claim 43 adapted for parenteral or oral administration.